title: [Significance of (18)F-FDG-PET/CT for staging and evaluation of therapeutic effect in patient with malignant lymphoma].
abstract: Imaging examination was already used for an overall assessment of disease sites in patient with malignant lymphoma, it is very important for the disease staging and evaluation of therapeutic effect. Staging is necessary to prevent hyper-or hypo-therapy as well as to minimize morbidity related to the radio-chemotherapy regimens given. (18)F-FDG-PET/CT, a functional imaging modality used for staging and monitoring response to treatment of a variety of human neoplasias, has higher sensitivity and specificity than conventional anatomical imaging. Baseline (18)F-FDG-PET/CT is used for the accurate staging, and helps to interpret the results of the middle therapy and post-therapy; middle therapy (18)F-FDG-PET/CT will be usually performed after 2-3 cycles of treatment, which can be used for risk assessment and judgement of therapeutic effect after treatment; posttherapy (18)F-FDG-PET/CT is used to evaluate the efficacy and monitoring of residual tumor, and to provide the basis for selecting treatment with or without high-intensity chemotherapy and transplantation. In this review, the significance of baseline, middle-therapy and post-therapy (18)F-FDG-PET/CT scanning for the diagnostic staging and evaluating therapeutic effect of malignant lymphoma as well as the characteristics of (18)F-FDG-PET/CT scanning for different pathologic types of lymphoma are summarized.
authors.affiliation: Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Li
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Zhu
authors.forename: Li
authors.initials: L
authors.lastname: Yu
mesh_terms: D019788:Fluorodeoxyglucose F18 / Q000627:therapeutic use; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000473:pathology; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D011379:Prognosis; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18